SUPPLEMENT
Q4 2024 — Other Financial Disclosures
Q4 2024PDF · 17 pages559 KB
Table 1: Sales by Segment 1 Table 2: Sales by Geographic Area 2 Table 3: Sales of Key Products/Franchises 3 - 7 Table 3a: Supplemental Sales Reconciliation 8 Table 4: Condensed Consolidated Statement of Earnings - QTD 9 Table 5: Condensed Consolidated Statement of Earnings - YTD 10 Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 11 Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 12 Table 8: Non-GAAP Adjusted Net Earnings 13 Table 9: Non-GAAP IBT and R&D Expense by Segment - QTD 14 Table 10: Non-GAAP IBT and R&D Expense by Segment - YTD 15 Table 11: Non-GAAP P&L Reconciliation 16 Fourth Quarter 2024 Other Financial Disclosures Table of Contents -- 1 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency Sales to customers by segment of business Innovative Medicine (1) U.S. 8,977 $ 8,079 11.1 % 11.1 - 33,970 $ 31,169 9.0 % 9.0 - International 5,355 5,643 (5.1) (1.0) (4.1) 22,994 23,590 (2.5) 1.3 (3.8) 14,332 13,722 4.4 6.1 (1.7) 56,964 54,759 4.0 5.7 (1.7) Innovative Medicine excluding COVID-19 Vaccine (1) U.S. 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 - International 5,355 5,599 (4.4) (0.3) (4.1) 22,796 22,473 1.4 5.5 (4.1) 14,332 13,678 4.8 6.5 (1.7) 56,766 53,642 5.8 7.5 (1.7) MedTech U.S. 4,227 3,930 7.6 7.6 - 16,332 15,275 6.9 6.9 - International 3,961 3,743 5.8 7.6 (1.8) 15,525 15,125 2.6 5.4 (2.8) 8,188 7,673 6.7 7.6 (0.9) 31,857 30,400 4.8 6.2 (1.4) U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4) Worldwide 22,520 21,395 5.3 6.7 (1.4) 88,821 85,159 4.3 5.9 (1.6) U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6) Worldwide excluding COVID-19 Vaccine (1) 22,520 $ 21,351 5.5 % 6.9 (1.4) 88,623 $ 84,042 5.5 % 7.0 (1.5) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales information schedules FOURTH QUARTER TWELVE MONTHS Percent Change -- 2 of 17 -- Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency Sales to customers by geographic area U.S. 13,204 $ 12,009 10.0 % 10.0 - 50,302 $ 46,444 8.3 % 8.3 - Europe 4,921 4,962 (0.8) (0.2) (0.6) 20,212 20,410 (1.0) (0.6) (0.4) Western Hemisphere excluding U.S. 1,135 1,166 (2.7) 17.6 (20.3) 4,714 4,549 3.6 20.4 (16.8) Asia-Pacific, Africa 3,260 3,258 0.1 0.9 (0.8) 13,593 13,756 (1.2) 2.3 (3.5) International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4) Worldwide 22,520 $ 21,395 5.3 % 6.7 (1.4) 88,821 $ 85,159 4.3 % 5.9 (1.6) Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) Percent Change 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency Sales to customers by geographic area (ex. COVID-19 Vaccine) U.S.* 13,204 $ 12,009 10.0 % 10.0 - 50,302 $ 46,444 8.3 % 8.3 - Europe(1) 4,921 4,918 0.1 0.7 (0.6) 20,014 19,293 3.7 4.1 (0.4) Western Hemisphere excluding U.S.* 1,135 1,166 (2.7) 17.6 (20.3) 4,714 4,549 3.6 20.4 (16.8) Asia-Pacific, Africa* 3,260 3,258 0.1 0.9 (0.8) 13,593 13,756 (1.2) 2.3 (3.5) International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6) Worldwide 22,520 $ 21,351 5.5 % 6.9 (1.4) 88,623 $ 84,042 5.5 % 7.0 (1.5) Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (1) Refer to supplemental sales information schedules *No COVID-19 Vaccine sales Percent Change FOURTH QUARTER TWELVE MONTHS Percent Change FOURTH QUARTER TWELVE MONTHS -- 3 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS INNOVATIVE MEDICINE SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency IMMUNOLOGY US 2,856 $ 3,033 -5.9% -5.9% - 11,355 $ 11,539 -1.6% -1.6% - Intl 1,383 1,562 -11.5% -6.5% -5.0% 6,473 6,513 -0.6% 4.0% -4.6% WW 4,238 4,595 -7.8% -6.1% -1.7% 17,828 18,052 -1.2% 0.4% -1.6% REMICADE US 231 294 -21.4% -21.4% - 1,009 1,143 -11.7% -11.7% - US Exports (3) 9 35 -73.3% -73.3% - 98 147 -33.0% -33.0% - Intl 117 100 16.5% 22.9% -6.4% 497 549 -9.5% -5.0% -4.5% WW 359 429 -16.5% -15.0% -1.5% 1,605 1,839 -12.8% -11.4% -1.4% SIMPONI / SIMPONI ARIA US 262 258 1.3% 1.3% - 1,082 1,124 -3.8% -3.8% - Intl 321 244 32.1% 44.2% -12.1% 1,108 1,073 3.3% 13.2% -9.9% WW 583 502 16.2% 22.1% -5.9% 2,190 2,197 -0.3% 4.5% -4.8% STELARA US 1,699 1,786 -4.9% -4.9% - 6,720 6,966 -3.5% -3.5% - Intl 650 967 -32.7% -29.6% -3.1% 3,641 3,892 -6.4% -3.3% -3.1% WW 2,349 2,753 -14.7% -13.6% -1.1% 10,361 10,858 -4.6% -3.4% -1.2% TREMFYA US 654 657 -0.6% -0.6% - 2,443 2,147 13.7% 13.7% - Intl 295 252 16.9% 21.7% -4.8% 1,227 999 22.8% 27.6% -4.8% WW 949 910 4.2% 5.6% -1.4% 3,670 3,147 16.6% 18.1% -1.5% OTHER IMMUNOLOGY US 0 2 * * - 3 11 -74.1% -74.1% - Intl 0 0 - - - 0 0 - - - WW 0 2 * * * 3 11 -74.1% -74.1% - INFECTIOUS DISEASES US 331 353 -6.4% -6.4% - 1,354 1,500 -9.8% -9.8% - Intl 443 498 -11.2% -9.8% -1.4% 2,042 2,918 -30.0% -29.3% -0.7% WW 774 852 -9.2% -8.4% -0.8% 3,396 4,418 -23.1% -22.7% -0.4% COVID-19 VACCINE US 0 0 - - - 0 0 - - - Intl 0 44 * * * 198 1,117 -82.4% -82.4% 0.0% WW 0 44 * * * 198 1,117 -82.4% -82.4% 0.0% EDURANT / rilpivirine US 7 9 -10.1% -10.1% - 31 35 -10.0% -10.0% - Intl 315 299 5.0% 5.6% -0.6% 1,241 1,115 11.2% 11.2% 0.0% WW 322 307 4.6% 5.1% -0.5% 1,272 1,150 10.6% 10.6% 0.0% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 321 341 -5.8% -5.8% - 1,311 1,446 -9.4% -9.4% - Intl 86 98 -12.9% -8.9% -4.0% 401 408 -1.7% 1.1% -2.8% WW 407 439 -7.4% -6.5% -0.9% 1,712 1,854 -7.7% -7.1% -0.6% OTHER INFECTIOUS DISEASES US 1 4 -53.1% -53.1% - 11 19 -41.0% -41.0% - Intl 43 58 -24.2% -22.4% -1.8% 203 278 -26.7% -23.9% -2.8% WW 45 62 -26.1% -24.4% -1.7% 214 297 -27.6% -25.0% -2.6% % Change % Change -- 4 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency NEUROSCIENCE US 1,148 1,022 12.3% 12.3% - 4,398 4,065 8.2% 8.2% - Intl 628 780 -19.6% -16.8% -2.8% 2,718 3,076 -11.6% -7.8% -3.8% WW 1,775 1,801 -1.5% -0.3% -1.2% 7,115 7,140 -0.4% 1.3% -1.7% CONCERTA / Methylphenidate US 33 39 -12.8% -12.8% - 134 230 -41.7% -41.7% - Intl 125 142 -11.5% -7.7% -3.8% 507 554 -8.4% -4.1% -4.3% WW 159 180 -11.7% -8.8% -2.9% 641 783 -18.1% -15.1% -3.0% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 796 733 8.6% 8.6% - 3,125 2,897 7.9% 7.9% - Intl 267 278 -4.0% -1.8% -2.2% 1,097 1,218 -9.9% -7.1% -2.8% WW 1,063 1,011 5.1% 5.7% -0.6% 4,222 4,115 2.6% 3.4% -0.8% SPRAVATO US 269 180 50.1% 50.1% - 929 589 57.8% 57.8% - Intl 28 26 7.1% 12.5% -5.4% 148 100 48.2% 51.2% -3.0% WW 297 206 44.6% 45.3% -0.7% 1,077 689 56.4% 56.8% -0.4% OTHER NEUROSCIENCE US 49 71 -31.0% -31.0% - 210 349 -39.8% -39.8% - Intl 206 334 -38.1% -35.4% -2.7% 965 1,204 -19.8% -15.1% -4.7% WW 255 404 -36.9% -34.6% -2.3% 1,175 1,553 -24.3% -20.7% -3.6% ONCOLOGY US 3,019 2,285 32.2% 32.2% - 10,854 8,462 28.3% 28.3% - Intl 2,476 2,334 6.1% 10.6% -4.5% 9,926 9,199 7.9% 12.1% -4.2% WW 5,497 4,618 19.0% 21.3% -2.3% 20,781 17,661 17.7% 19.8% -2.1% CARVYKTI US 304 145 * * - 869 469 85.2% 85.2% - Intl 31 13 * * * 94 30 * * * WW 334 159 * * * 963 500 92.7% 92.7% 0.0% DARZALEX US 1,799 1,395 28.9% 28.9% - 6,588 5,277 24.8% 24.8% - Intl 1,285 1,155 11.3% 17.0% -5.7% 5,082 4,467 13.8% 19.1% -5.3% WW 3,084 2,550 20.9% 23.5% -2.6% 11,670 9,744 19.8% 22.2% -2.4% ERLEADA US 342 287 19.0% 19.0% - 1,282 1,065 20.3% 20.3% - Intl 442 361 22.4% 25.7% -3.3% 1,717 1,322 29.8% 32.9% -3.1% WW 784 647 20.9% 22.7% -1.8% 2,999 2,387 25.6% 27.3% -1.7% IMBRUVICA US 250 255 -2.0% -2.0% - 1,020 1,051 -3.0% -3.0% - Intl 481 533 -9.6% -6.8% -2.8% 2,018 2,214 -8.8% -6.3% -2.5% WW 731 788 -7.2% -5.2% -2.0% 3,038 3,264 -6.9% -5.2% -1.7% TECVAYLI US 108 102 5.6% 5.6% - 418 334 25.3% 25.3% - Intl 38 24 59.9% 71.6% -11.7% 131 61 * * * WW 146 126 15.8% 18.0% -2.2% 549 395 38.8% 39.8% -1.0% ZYTIGA / abiraterone acetate US 9 9 -7.3% -7.3% - 34 50 -32.2% -32.2% - Intl 127 191 -33.6% -30.7% -2.9% 597 837 -28.6% -24.6% -4.0% WW 135 201 -32.4% -29.6% -2.8% 631 887 -28.8% -25.0% -3.8% OTHER ONCOLOGY US 208 90 * * - 643 215 * * - Intl 74 58 25.5% 30.6% -5.1% 288 269 7.1% 10.4% -3.3% WW 282 148 90.4% 92.4% -2.0% 931 484 92.5% 94.3% -1.8% % Change % Change -- 5 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency PULMONARY HYPERTENSION US 819 733 11.6% 11.6% - 3,143 2,697 16.5% 16.5% - Intl 274 282 -3.2% 1.2% -4.4% 1,140 1,117 2.0% 8.2% -6.2% WW 1,092 1,017 7.4% 8.7% -1.3% 4,282 3,815 12.3% 14.1% -1.8% OPSUMIT US 385 368 4.8% 4.8% - 1,520 1,292 17.7% 17.7% - Intl 160 169 -5.2% -2.5% -2.7% 664 681 -2.4% 1.1% -3.5% WW 545 536 1.7% 2.5% -0.8% 2,184 1,973 10.7% 11.9% -1.2% UPTRAVI US 391 348 12.3% 12.3% - 1,511 1,326 13.9% 13.9% - Intl 75 70 5.7% 11.2% -5.5% 307 255 20.1% 27.3% -7.2% WW 465 419 11.2% 12.1% -0.9% 1,817 1,582 14.9% 16.1% -1.2% OTHER PULMONARY HYPERTENSION US 42 18 * * - 112 79 41.8% 41.8% - Intl 40 45 -10.0% -0.4% -9.6% 169 182 -6.9% 8.2% -15.1% WW 82 61 32.3% 39.3% -7.0% 281 260 7.9% 18.3% -10.4% CARDIOVASCULAR / METABOLISM / OTHER US 805 652 23.3% 23.3% - 2,866 2,906 -1.4% -1.4% - Intl 153 185 -17.6% -15.1% -2.5% 696 765 -9.1% -7.1% -2.0% WW 957 837 14.3% 14.8% -0.5% 3,562 3,671 -3.0% -2.6% -0.4% XARELTO US 676 525 28.5% 28.5% - 2,373 2,365 0.3% 0.3% - Intl - - - - - - - - - - WW 676 525 28.5% 28.5% - 2,373 2,365 0.3% 0.3% - OTHER US 130 127 1.5% 1.5% - 494 541 -8.8% -8.8% - Intl 153 185 -17.6% -15.1% -2.5% 696 765 -9.1% -7.1% -2.0% WW 281 312 -9.8% -8.3% -1.5% 1,189 1,306 -8.9% -7.8% -1.1% TOTAL INNOVATIVE MEDICINE US 8,977 8,079 11.1% 11.1% - 33,970 31,169 9.0% 9.0% - Intl 5,355 5,643 -5.1% -1.0% -4.1% 22,994 23,590 -2.5% 1.3% -3.8% WW 14,332 $ 13,722 $ 4.4% 6.1% -1.7% 56,964 $ 54,759 4.0% 5.7% -1.7% See footnotes at end of schedule % Change % Change -- 6 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS MEDTECH SEGMENT (2) 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency CARDIOVASCULAR (4) US 1,221 $ 971 25.8% 25.8% - 4,513 $ 3,633 24.2% 24.2% - Intl 841 698 20.6% 22.0% -1.4% 3,194 2,717 17.6% 20.9% -3.3% WW 2,062 1,669 23.6% 24.2% -0.6% 7,707 6,350 21.4% 22.8% -1.4% ELECTROPHYSIOLOGY US 681 667 2.1% 2.1% - 2,738 2,458 11.4% 11.4% - Intl 640 572 11.7% 13.3% -1.6% 2,529 2,230 13.4% 17.0% -3.6% WW 1,321 1,239 6.6% 7.3% -0.7% 5,267 4,688 12.3% 14.0% -1.7% ABIOMED US 308 276 11.3% 11.3% - 1,213 1,066 13.7% 13.7% - Intl 77 64 19.8% 21.1% -1.3% 284 240 18.2% 20.3% -2.1% WW 384 340 12.9% 13.2% -0.3% 1,496 1,306 14.5% 14.9% -0.4% SHOCKWAVE (5) US 202 - * * - 442 - * * - Intl 56 - * * - 122 - * * - WW 258 - * * - 564 - * * - OTHER CARDIOVASCULAR (4) US 31 28 11.1% 11.1% - 120 109 10.7% 10.7% - Intl 68 61 12.1% 12.3% -0.2% 260 247 5.3% 7.3% -2.0% WW 99 89 11.8% 12.0% -0.2% 380 356 6.9% 8.4% -1.5% ORTHOPAEDICS US 1,460 1,425 2.4% 2.4% - 5,689 5,525 3.0% 3.0% - Intl 856 843 1.6% 2.5% -0.9% 3,470 3,417 1.5% 3.0% -1.5% WW 2,315 2,268 2.1% 2.5% -0.4% 9,158 8,942 2.4% 3.0% -0.6% HIPS US 272 266 2.5% 2.5% - 1,057 996 6.2% 6.2% - Intl 146 132 10.6% 11.7% -1.1% 581 564 3.0% 4.6% -1.6% WW 418 398 5.2% 5.6% -0.4% 1,638 1,560 5.0% 5.6% -0.6% KNEES US 238 242 -1.5% -1.5% - 922 896 2.9% 2.9% - Intl 160 144 10.7% 11.3% -0.6% 623 559 11.3% 12.4% -1.1% WW 398 387 3.1% 3.3% -0.2% 1,545 1,456 6.1% 6.5% -0.4% TRAUMA US 514 487 5.5% 5.5% - 2,013 1,949 3.3% 3.3% - Intl 250 255 -1.9% -0.5% -1.4% 1,036 1,030 0.6% 2.1% -1.5% WW 764 741 3.0% 3.5% -0.5% 3,049 2,979 2.3% 2.9% -0.6% SPINE, SPORTS & OTHER US 434 430 1.1% 1.1% - 1,696 1,684 0.7% 0.7% - Intl 300 311 -3.6% -2.9% -0.7% 1,230 1,263 -2.6% -1.2% -1.4% WW 735 742 -0.9% -0.6% -0.3% 2,926 2,947 -0.7% -0.1% -0.6% % Change % Change -- 7 of 17 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) FOURTH QUARTER TWELVE MONTHS 2024 2023 Reported Operational (1) Currency 2024 2023 Reported Operational (1) Currency SURGERY US 1,038 1,047 -0.9% -0.9% - 4,003 4,031 -0.7% -0.7% - Intl 1,469 1,484 -1.0% 1.4% -2.4% 5,842 6,006 -2.7% 0.6% -3.3% WW 2,507 2,530 -0.9% 0.4% -1.3% 9,845 10,037 -1.9% 0.1% -2.0% ADVANCED US 478 468 2.0% 2.0% - 1,838 1,833 0.2% 0.2% - Intl 673 698 -3.6% -1.6% -2.0% 2,650 2,837 -6.6% -3.5% -3.1% WW 1,151 1,167 -1.4% -0.1% -1.3% 4,488 4,671 -3.9% -2.0% -1.9% GENERAL US 560 579 -3.1% -3.1% - 2,165 2,198 -1.5% -1.5% - Intl 795 785 1.4% 4.0% -2.6% 3,192 3,168 0.8% 4.3% -3.5% WW 1,357 1,364 -0.5% 1.0% -1.5% 5,358 5,366 -0.2% 2.0% -2.2% VISION US 509 487 4.5% 4.5% - 2,128 2,086 2.0% 2.0% - Intl 794 721 10.2% 12.2% -2.0% 3,018 2,986 1.1% 3.7% -2.6% WW 1,303 1,208 7.9% 9.1% -1.2% 5,146 5,072 1.5% 3.0% -1.5% CONTACT LENSES / OTHER US 396 374 6.0% 6.0% - 1,684 1,626 3.6% 3.6% - Intl 541 508 6.4% 8.5% -2.1% 2,049 2,076 -1.3% 1.8% -3.1% WW 937 882 6.3% 7.4% -1.1% 3,733 3,702 0.8% 2.6% -1.8% SURGICAL US 113 114 -0.4% -0.4% - 444 460 -3.4% -3.4% - Intl 252 212 19.3% 21.1% -1.8% 969 910 6.5% 8.2% -1.7% WW 365 326 12.4% 13.6% -1.2% 1,413 1,370 3.2% 4.3% -1.1% TOTAL MEDTECH US 4,227 3,930 7.6% 7.6% - 16,332 15,275 6.9% 6.9% - Intl 3,961 3,743 5.8% 7.6% -1.8% 15,525 15,125 2.6% 5.4% -2.8% WW 8,188 $ 7,673 $ 6.7% 7.6% -0.9% 31,857 $ 30,400 4.8% 6.2% -1.4% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Reported as U.S. sales (4) Previously referred to as Interventional Solutions (5) Acquired on May 31, 2024 % Change Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely % Change -- 8 of 17 -- 2024 2023 Total Operations Currency 2024 2023 Total Operations Currency Innovative Medicine U.S. 8,977 $ 8,079 11.1 11.1 - 33,970 $ 31,169 9.0 9.0 - International 5,355 5,643 (5.1) (1.0) (4.1) 22,994 23,590 (2.5) 1.3 (3.8) Worldwide 14,332 13,722 4.4 6.1 (1.7) 56,964 54,759 4.0 5.7 (1.7) COVID-19 Vaccine U.S. - - - - - - - - - - International - 44 * * * 198 1,117 (82.4) (82.4) 0.0 Worldwide - 44 * * * 198 1,117 (82.4) (82.4) 0.0 Innovative Medicine excluding COVID-19 Vaccine U.S. 8,977 8,079 11.1 11.1 - 33,970 31,169 9.0 9.0 - International 5,355 5,599 (4.4) (0.3) (4.1) 22,796 22,473 1.4 5.5 (4.1) Worldwide 14,332 13,678 4.8 6.5 (1.7) 56,766 53,642 5.8 7.5 (1.7) Worldwide U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - International 9,316 9,386 (0.7) 2.5 (3.2) 38,519 38,715 (0.5) 2.9 (3.4) Worldwide 22,520 21,395 5.3 6.7 (1.4) 88,821 85,159 4.3 5.9 (1.6) COVID-19 Vaccine U.S. - - - - - - - - - - International - 44 * * * 198 1,117 (82.4) (82.4) 0.0 Worldwide - 44 * * * 198 1,117 (82.4) (82.4) 0.0 Worldwide U.S. 13,204 12,009 10.0 10.0 - 50,302 46,444 8.3 8.3 - International 9,316 9,342 (0.3) 2.9 (3.2) 38,321 37,598 1.9 5.5 (3.6) Worldwide excluding COVID-19 Vaccine 22,520 $ 21,351 5.5 6.9 (1.4) 88,623 $ 84,042 5.5 7.0 (1.5) Europe 4,921 $ 4,962 (0.8) (0.2) (0.6) 20,212 $ 20,410 (1.0) (0.6) (0.4) Europe COVID-19 Vaccine Sales - 44 * * * 198 1,117 (82.4) (82.4) 0.0 Europe excluding COVID-19 Vaccine Sales 4,921 $ 4,918 0.1 0.7 (0.6) 20,014 $ 19,293 3.7 4.1 (0.4) * Percentage greater than 100% or not meaningful Percent Change FOURTH QUARTER Percent Change Supplemental Sales Information (Unaudited) (Dollars in Millions) TWELVE MONTHS -- 9 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 22,520 $ 100.0 21,395 $ 100.0 5.3 Cost of products sold 7,128 31.6 6,798 31.8 4.9 Gross Profit 15,392 68.4 14,597 68.2 5.4 Selling, marketing and administrative expenses 6,453 28.6 5,810 27.1 11.1 Research and development expense 5,298 23.5 4,480 20.9 18.3 In-process research and development impairments 17 0.1 58 0.3 Interest (income) expense, net (144) (0.6) (212) (1.0) Other (income) expense, net (161) (0.7) (421) (2.0) Restructuring 42 0.2 56 0.3 Earnings before provision for taxes on income 3,887 17.3 4,826 22.6 (19.5) Provision for taxes on income 456 2.1 694 3.3 (34.3) Net earnings from Continuing Operations 3,431 $ 15.2 4,132 $ 19.3 (17.0) Net earnings/(loss) from Discontinued Operations, net of tax - (83) Net earnings 3,431 $ 4,049 $ Net earnings per share (Diluted) from Continuing Operations 1.41 $ 1.70 $ (17.1) Net earnings/(loss) per share (Basic) from Discontinued Operations* - $ (0.03) $ Average shares outstanding (Diluted) 2,427.1 2,430.7 Effective tax rate from Continuing Operations 11.7 % 14.4 % Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 5,421 $ 24.1 6,237 $ 29.2 (13.1) Net earnings from Continuing Operations 4,946 $ 22.0 5,562 $ 26.0 (11.1) Net earnings per share (Diluted) from Continuing Operations 2.04 $ 2.29 $ (10.9) Effective tax rate from Continuing Operations 8.8 % 10.8 % * Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive. (1) See Reconciliation of Non-GAAP Financial Measures. FOURTH QUARTER 2024 2023 -- 10 of 17 -- Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers 88,821 $ 100.0 85,159 $ 100.0 4.3 Cost of products sold 27,471 30.9 26,553 31.2 3.5 Gross Profit 61,350 69.1 58,606 68.8 4.7 Selling, marketing and administrative expenses 22,869 25.7 21,512 25.2 6.3 Research and development expense 17,232 19.4 15,085 17.7 14.2 In-process research and development impairments 211 0.2 313 0.4 Interest (income) expense, net (577) (0.6) (489) (0.6) Other (income) expense, net 4,694 5.3 6,634 7.8 Restructuring 234 0.3 489 0.6 Earnings before provision for taxes on income 16,687 18.8 15,062 17.7 10.8 Provision for taxes on income 2,621 3.0 1,736 2.1 51.0 Net earnings from Continuing Operations 14,066 $ 15.8 13,326 $ 15.6 5.6 Net earnings from Discontinued Operations, net of tax - 21,827 Net earnings 14,066 $ 35,153 $ Net earnings per share (Diluted) from Continuing Operations 5.79 $ 5.20 $ 11.3 Net earnings per share (Diluted) from Discontinued Operations - $ 8.52 $ Average shares outstanding (Diluted) 2,429.4 2,560.4 Effective tax rate from Continuing Operations 15.7 % 11.5 % Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) Earnings before provision for taxes on income from Continuing Operations 28,979 $ 32.6 29,811 $ 35.0 (2.8) Net earnings from Continuing Operations 24,242 $ 27.3 25,409 $ 29.8 (4.6) Net earnings per share (Diluted) from Continuing Operations 9.98 $ 9.92 $ 0.6 Effective tax rate from Continuing Operations 16.3 % 14.8 % (1) See Reconciliation of Non-GAAP Financial Measures. TWELVE MONTHS 2024 2023 -- 11 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.4% 6.7% 5.3% U.S. 11.1% 7.6% 10.0% International (5.1)% 5.8% (0.7)% WW Currency (1.7) (0.9) (1.4) U.S. - - - International (4.1) (1.8) (3.2) WW Operational 6.1% 7.6% 6.7% U.S. 11.1% 7.6% 10.0% International (1.0)% 7.6% 2.5% Shockwave (3.4) (1.2) U.S. (5.1) (1.7) International (1.5) (0.6) All Other Acquisitions and Divestitures (A&D) 0.2 0.4 0.2 U.S. 0.1 0.8 0.3 International 0.3 0.0 0.1 WW Adjusted Operational Ex A&D 6.3% 4.6% 5.7% U.S. 11.2% 3.3% 8.6% International (0.7)% 6.1% 2.0% COVID-19 Vaccine 0.4 0.2 U.S. 0.0 0.0 International 0.7 0.4 WW Adjusted Operational Ex A&D & COVID-19 Vaccine 6.7% 4.6% 5.9% U.S. 11.2% 3.3% 8.6% International 0.0% 6.1% 2.4% Adjusted Operational Sales Growth FOURTH QUARTER 2024 ACTUAL vs. 2023 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 12 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Innovative Medicine MedTech Total WW As Reported 4.0% 4.8% 4.3% U.S. 9.0% 6.9% 8.3% International (2.5)% 2.6% (0.5)% WW Currency (1.7) (1.4) (1.6) U.S. - - - International (3.8) (2.8) (3.4) WW Operational 5.7% 6.2% 5.9% U.S. 9.0% 6.9% 8.3% International 1.3% 5.4% 2.9% Shockwave (1.9) (0.7) U.S. (2.9) (1.0) International (0.8) (0.3) All Other Acquisitions and Divestitures (A&D) 0.1 0.4 0.2 U.S. 0.1 0.8 0.3 International 0.2 0.1 0.1 WW Adjusted Operational Ex A&D 5.8% 4.7% 5.4% U.S. 9.1% 4.8% 7.6% International 1.5% 4.7% 2.7% COVID-19 Vaccine 1.8 1.1 U.S. 0.0 0.0 International 4.2 2.6 WW Adjusted Operational Ex A&D & COVID-19 Vaccine 7.6% 4.7% 6.5% U.S. 9.1% 4.8% 7.6% International 5.7% 4.7% 5.3% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth TWELVE MONTHS 2024 ACTUAL vs. 2023 ACTUAL Segments -- 13 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2024 2023 2024 2023 Net Earnings from Continuing Operations, after tax- as reported $3,431 $4,132 $14,066 $13,326 Pre-tax Adjustments Litigation related (16) 166 5,450 7,152 Intangible Asset Amortization expense 1,171 1,148 4,526 4,532 COVID-19 Vaccine related costs 1 23 10 100 663 Restructuring related 2 62 139 269 798 Medical Device Regulation 3 47 88 204 311 Acquisition, integration and divestiture related 298 237 1,226 339 (Gains)/losses on securities (68) (435) 306 641 IPR&D impairments 17 58 211 313 Tax Adjustments Tax impact on special item adjustments 4 (80) 75 (2,135) (2,694) Tax legislation and other tax related 61 (56) 19 28 Adjusted Net Earnings from Continuing Operations, after tax $4,946 $5,562 $24,242 $25,409 Average shares outstanding (Diluted) 2,427.1 2,430.7 2,429.4 2,560.4 Adjusted net earnings per share from Continuing Operations (Diluted) $2.04 $2.29 $9.98 $9.92 Operational adjusted net earnings per share from Continuing Operations (Diluted) $2.05 $9.99 Notes: 1 COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024. 2 3 4 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Fourth Quarter Twelve Months Ended In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024. In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to the market and product exits. replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025. -- 14 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2024 2023 2024 2023 2024 2023 2024 2023 Reported Income Before Tax by Segment From Continuing Operations $ 4,009 4,238 72 404 (194) 184 3,887 4,826 % to Sales 28.0% 30.9% 0.9% 5.3% -0.9% 0.9% 17.3% 22.6% Intangible asset amortization expense 685 747 486 401 - - 1,171 1,148 In-process research and development impairments 17 - - 58 - - 17 58 Litigation related (41) 17 (29) 149 54 - (16) 166 Loss/(gain) on securities (50) (112) (18) (59) - (264) (68) (435) Restructuring related 2 55 60 84 - - 62 139 Acquisition, integration and divestiture related 12 175 268 62 18 - 298 237 Medical Device Regulation - - 47 88 - - 47 88 COVID-19 Vaccine related costs 23 10 - - - - 23 10 Adjusted Income Before Tax by Segment From Continuing Operations $ 4,657 5,130 886 1,187 (122) (80) 5,421 6,237 % to Sales 32.5% 37.4% 10.8% 15.5% -0.5% -0.4% 24.1% 29.2% *Estimated as of 1/22/2025 As Reported Research and development expense** $ 3,698 3,357 1,600 1,123 5,298 4,480 % to Sales 25.8% 24.5% 19.5% 14.6% 23.5% 20.9% **Includes the following Acquired IPR&D: Laminar - Q4 2023 390 390 V-Wave - Q4 2024 540 540 Total 540 390 540 390 Q4 QTD - Income Before Tax* and Research & Development Expense by Segment Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 15 of 17 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2024 2023 2024 2023 2024 2023 2024 2023 Reported Income Before Tax by Segment From Continuing Operations $ 18,919 18,246 3,740 4,669 (5,972) (7,853) 16,687 15,062 % to Sales 33.2% 33.3% 11.7% 15.4% -6.7% -9.2% 18.8% 17.7% Intangible asset amortization expense 2,772 2,983 1,754 1,549 - - 4,526 4,532 In-process research and development impairments 211 206 - 107 - - 211 313 Litigation related 358 (108) (14) 190 5,106 7,070 5,450 7,152 Loss/(gain) on securities (76) 362 30 (102) 352 381 306 641 Restructuring related 102 479 167 319 - - 269 798 Acquisition, integration and divestiture related 66 175 1,015 164 145 - 1,226 339 Medical Device Regulation - - 204 311 - - 204 311 COVID-19 Vaccine related costs 100 663 - - - - 100 663 Adjusted Income Before Tax by Segment From Continuing Operations $ 22,452 23,006 6,896 7,207 (369) (402) 28,979 29,811 % to Sales 39.4% 42.0% 21.6% 23.7% -0.4% -0.5% 32.6% 35.0% *Estimated as of 1/22/2025 As Reported Research and development expense** $ 13,529 11,963 3,703 3,122 17,232 15,085 % to Sales 23.8% 21.8% 11.6% 10.3% 19.4% 17.7% **Includes the following Acquired IPR&D: Laminar - Q4 2023 390 390 Yellow Jersey (NM26 bispecific antibody) - Q3 2024 1,250 1,250 V-Wave -Q4 2024 540 540 Total 1,250 540 390 1,790 390 Q4 YTD - Income Before Tax* and Research & Development Expense by Segment Dollars in Millions Innovative Medicine MedTech Unallocated Worldwide Total -- 16 of 17 -- Fourth Quarter Dec. 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Fourth Quarter Dec. 29, 2024 Non-GAAP Cost of products sold 7,128 $ (1,162) (20) (153) (18) - - 5,775 Selling, marketing and admin expenses 6,453 (4) 6,449 Research and development expense 5,298 - (25) (6) 5,267 Other (Income) / Expense (161) (9) 16 - (145) 68 (17) (248) In-process research and development impairments 17 (17) - - Restructuring 42 (42) - Provision for taxes on income 456 171 (158) 4 3 80 (34) 9 5 (61) 475 Net Earnings from Continuing Operations 3,431 1,000 142 13 59 218 (34) 38 18 61 4,946 Fourth Quarter Dec. 31, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Fourth Quarter Dec. 31, 2023 Non-GAAP Cost of products sold 6,798 $ (1,131) (83) (42) (12) - 5,530 Selling, marketing and admin expenses 5,810 (8) 5,802 Research and development expense 4,480 (16) (38) (1) 4,425 Other (Income) / Expense (421) (17) (166) - (221) 435 3 (387) In-process research and development impairments 58 (58) - Restructuring 56 (56) - Provision for taxes on income 694 175 (134) 13 16 30 (191) 16 - 56 675 Net Earnings from Continuing Operations 4,132 973 300 45 123 207 (244) 72 10 (56) 5,562 Twelve Months Dec. 29, 2024 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Twelve Months Dec. 29, 2024 Non-GAAP Cost of products sold 27,471 $ (4,517) (35) (359) (84) (8) 22,468 Selling, marketing and admin expenses 22,869 (16) - 22,853 Research and development expense 17,232 (69) (104) (25) 17,034 Other (Income) / Expense 4,694 (9) (5,450) - (798) (306) (67) (1,936) In-process research and development impairments 211 (211) - - - - - Restructuring 234 (234) - Provision for taxes on income 2,621 644 1,066 47 45 302 (29) 38 22 (19) 4,737 Net Earnings from Continuing Operations 14,066 3,882 4,384 164 224 924 335 166 78 19 24,242 Twelve Months Dec. 31, 2023 GAAP Intangible asset amortization Litigation related Restructuring related Medical Device Regulation Twelve Months Dec. 31, 2023 Non-GAAP Cost of products sold 26,553 $ (4,511) (309) (133) (189) 21,411 Selling, marketing and admin expenses 21,512 (29) 21,483 Research and development expense 15,085 (32) (149) (99) 14,805 Other (Income) / Expense 6,634 (21) (7,152) - (307) (641) (375) (1,862) In-process research and development impairments 313 (313) - - Restructuring 489 (489) - Provision for taxes on income 1,736 707 1,505 70 157 52 (9) 57 155 (28) 4,402 Net Earnings from Continuing Operations 13,326 3,825 5,647 243 641 287 650 254 508 28 25,409 In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related Year to Date Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related In-process research and development impairments Acquisition, integration and divestiture related (Loss)/gain on securities COVID-19 Vaccine Related Costs Tax legislation and other tax related -- 17 of 17 --